QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ADMA

QT78ADMA Biologics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
8.31
-0.11-1.31%
OverviewShort InterestFilings
ADMAQT78ADMA Biologics, Inc.·NASDAQ
OverviewShort InterestFilings
8.31-1.31%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E12.02EPS (ttm)
0.68
Insider Own18.47%
Shs Outstand231.77M
Perf Week-0.12%
Market Cap1.95BForward P/E8.19EPS next Y1.01Insider Trans0.06%Shs Float-Perf Month-3.71%
Enterprise Value2.02BPEG-EPS next Q0.16Inst Own-Short Float-Perf Quarter-44.67%
Income162.37MP/S3.83EPS this Y21.69%Inst Trans-Short Ratio-Perf Half Y-56.65%
Sales509.86MP/B5.09EPS next Y22.65%ROA24.86%Short Interest-Perf YTD-54.44%
Book/sh1.68P/C15.49EPS next 5Y21.61%ROE38.97%52W High20.46 -59.38%Perf Year-56.01%
Cash/sh0.60P/FCF18.09EPS past 3/5Y-ROIC27.81%52W Low7.21 15.26%Perf 3Y-
Dividend Est.-EV/EBITDA9.11Sales past 3/5Y49.06% 64.76%Gross Margin61.27%Volatility2.55% 2.79%Perf 5Y-
Dividend TTM-EV/Sales3.96EPS Y/Y TTM-13.58%Oper. Margin40.57%ATR (14)0.39Perf 10Y-
Dividend Ex-Date-Quick Ratio3.93Sales Y/Y TTM19.48%Profit Margin32.43%RSI (14)45.41Recom2.25
Dividend Gr. 3/5Y-Current Ratio6.95EPS Q/Q35.71%SMA202.03%Beta1.07Target Price21.00
Payout0.00%Debt/Eq0.52Sales Q/Q-0.87%SMA50-9.35%Rel Volume1.61Prev Close8.42
Employees685LT Debt/Eq0.16EarningsAug 05SMA200-41.98%Avg Volume5.55MPrice8.31
IPO DateOct 17, 2013Option/ShortYes / YesEPS/Sales Surpr.-1.71% -18.57%Net Debt/EBITDA0.30Volume8,921,869Change-1.31%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ResumedRaymond JamesOutperform$21
May-07-26ReiteratedCanaccord GenuityBuy$21 → $18
Apr-20-26InitiatedCanaccordBuy$21
Apr-13-26ReiteratedMizuho Securities$30 → $24
Mar-26-26DowngradeCantor FitzgeraldOverweight → Neutral
Oct-14-24ReiteratedH.C. WainwrightBuy$4.50 → $18
Jun-20-24ReiteratedMizuho Securities$6.00 → $14
Jan-03-23ReiteratedH.C. WainwrightBuy$4.00 → $4.50
Nov-10-22ReiteratedMizuho Securities$6.00
Jul-25-22ReiteratedH.C. WainwrightBuy$4.00
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue509510426
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A198217207
Gross Profit313293220
Selling, General and Administrative Excl. Other969274
Research and Development752
Other Operating Expense245
Operating Income207191139
Interest Expense8714
Unusual Expense
———
Non-Operating Income (Expense)-62-1
Net Income Before Taxes207183126
Income Taxes4136-72
Consolidated Net Income164147198
Net Income From Continuing Operations164147198
Net Income164147198
EPS (Recurring)0.690.620.85
EPS (Basic, Before Extraordinaries)0.690.620.85
EPS (Diluted)0.680.600.81
EBITDA221198148
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio12.2230.40—
Price To Sales Ratio3.858.51—
Gross Margin61.4957.4551.64
Operating Margin40.6737.4532.63
Net Margin32.2228.8246.48
Shares Outstanding236238233
Market Capitalization1,9614,341—
Operating Lease Expense
———
Insider Trading Volume
$8.77$7.86$6.95$6.04$5.13● Close Price0.00M2.47M4.95M7.42M9.90MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Grossman Jerrold BDirectorMay 27 '26Buy7.916,40050,624520,284May 28 12:00 AM
Grossman Jerrold BDirectorMay 12 '26Buy8.0112,500100,125513,884May 14 12:00 AM
Grossman Jerrold BDirectorMay 11 '26Buy8.0112,500100,125501,384May 12 12:00 AM
Grossman Adam SPresident and CEOMar 16 '26Option Exercise5.4030,000162,0002,133,777Mar 17 12:00 AM
Grossman Adam SPresident and CEOMar 16 '26Sale15.1621,000318,3602,112,777Mar 17 12:00 AM
Guiheen Lawrence P.DirectorMar 13 '26Option Exercise3.6660,000219,600135,520Mar 17 12:00 AM
Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceMar 09 '26Option Exercise3.2020,19264,660476,696Mar 10 12:00 AM
Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceMar 09 '26Sale15.6310,096157,800466,600Mar 10 12:00 AM
ELMS STEVEDirectorMar 06 '26Buy15.397,000107,7302,045,730Mar 09 12:00 AM
ELMS STEVEDirectorMar 05 '26Buy15.677,000109,6902,038,730Mar 09 12:00 AM
Grossman Adam SPresident and CEOFeb 17 '26Option Exercise5.4030,000162,0002,305,379Feb 17 12:00 AM
Grossman Adam SPresident and CEOFeb 17 '26Sale16.0821,000337,6802,284,379Feb 17 12:00 AM
Grossman Adam SPresident and CEODec 15 '25Option Exercise5.4030,000162,0002,028,850Dec 16 12:00 AM
Grossman Adam SPresident and CEODec 15 '25Sale19.7921,000415,5902,007,850Dec 16 12:00 AM
Grossman Adam SPresident and CEONov 19 '25Sale16.0021,000336,0002,013,850Nov 21 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR